Breaking News, Collaborations & Alliances

ThinkCyte, FIMM Partner to Advance Treatments for Blood Cancer

Will everage ThinkCyte's AI-driven cell characterization and sorting platform and FIMM's biorepository of clinically annotated leukemia samples.

ThinkCyte, a biotechnology company that develops innovative scientific instruments, entered into a strategic research partnership with the Institute for Molecular Medicine Finland (FIMM-HiLIFE), University of Helsinki, to advance the understanding of leukemia and its treatment. The partnership leverages ThinkCyte’s new artificial intelligence (AI)-driven cell characterization and sorting platform, VisionSort, and FIMM’s biorepository of clinically annotated leukemia samples and exper...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters